2 Definition Many cancers are associated with the abnormal production of some molecules l which h can be measured in plasma. These molecules are known as tumor markers.
3 A good tumor maker should have those properties: 1. A tumor marker should be present in or produced by tumor itself. 2. A tumor marker should not be present in healthy tissues. 3. Plasma level of a tumor marker should be at a minimum level in healthy subjects and in benign conditions.
4 4. A tumor marker should be specific for a tissue, it should have different immunological properties when it is synthesized in other tissues. 5. Plasma level of the tumor marker should be in proportion to the both size of tumor and activity of tumor. 6 H lf lif f t k h ld t 6. Half life of a tumor marker should not be very long
5 7. A tumor marker should be present ent in plasma at a detectable level, even though tumor size is very small
6 Tumor markers can be classified as respect with the type of the molecule: 1. Enzymes or isoenzymes (ALP, PAP) 2. Hormones (calcitonin) 3. Oncofetal antigens (AFP, CEA) 4. Carbonhydrate epitopes p recognised by monoclonal antibodies (CA 15-3,CA 19-9, CA125) 5. Receptors (Estrogen, progesterone)
7 6. Genetic changes (mutations tion in some oncogenes and tumor suppressor genes. Some mutations in BRCA1 and 2 have been linked to hereditary breast and ovarian cancer)
8 Potential ti uses of tumor markers Screening in general population Differential diagnosis of symptomatic patients Clinical staging of cancer Estimating tumor volume As a prognostic indicator for disease progression Evaluating the success of treatment
9 Detecting the recurrence of cancer Monitoring reponse to therapy Radioimmunolocalization of tumor masses
10 Screening In order to use a tumor marker for screening in the presence of cancer in asymptomatic individuals in general population, the marker should be produced by tumor cells and not be present in healthy people. However, most tumor markers are present in normal, benign and cancer tissues and are not spesific enough to be used for screening cancer.
11 DIAGNOSIS Few markers are specific for a single individual tumor, most are found with different tumors of the same tissue type. They are present in higher quantities in blood from cancer patients than in blood from both healthy subjects and patients with benign diseases.
12 Some tumor markers have a plasma level in proportion to the size of tumor while some tumor markers have a plasma level in proportion to the activity of tumor. The clinical staging of cancer is aidded by quantitiation of the marker.
13 PROGNOSIS AND PROGRESSION Serum level of marker reflects tumor burden. The level of the marker at the time of diagnosis may be used as a prognostic indicator for disease progression and patient survival. After successful initial treatment, such as surgery, the marker value should decrease. The rate of the decrease can be predicted by using the half life of the marker.
14 The magnitude of marker reduction may reflect the degree of success of the treatment. In the case of recurrence of cancer, marker increases again. Most tumor marker values correlate with the effectiveness of treatment.
15 ENZYMES Alkaline Phosphatase (ALP) Increased alkaline phosphatase activities are seen in primary or secondary liver cancer. Its level may be helpful in evaluating metastatic cancer with bone or liver involvement. Placental ALP, isoenzyme, elevates in a variety of malignancies, including ovarian, lung, gastrointestinal cancers and Hodgkin s disease.
16 Prostatic acid phosphatase (PAP) It is used for staging prostate cancer and for monitoring therapy. Increased PAP activity it may be seen in osteogenic sarcoma, multiple myeloma and bone metastasis of other cancers and in some benign conditions such as osteoporosis and hyperparathyroidism.
17 Prostate Specific Antigen (PSA) The clinical l use of PAP has been replaced ed by PSA. PSA is much more specific for screening or for detection early cancer. It is found mainly in prostatic tissue. PSA exists in two major forms in blood circulation. The majority of PSA is complexed with some proteins. A minor component of PSA is free.
18 PSA testing ti itself is not effective in detecting early prostate cancer. Other prostatic diseases, urinary bladder cateterization and digital rectal examination may lead an increased PSA level l in serum. The ratio between free and total PSA is an reliable marker for differentiation of prostatic cancer from benign prostatic hyperplasia. p
19 The use of PSA should be together with digital rectal examination and followed by transrectal ultrasonography for an accurate diagnosis of cancer. Serum level of PSA was found to be correlated with clinical stage, grade and metastasis
20 The greatest clinical use of PSA is in the monitoring of treatment. This treatment includes radical prostatectomy, radiation therapy and antiandrogen therapy. The PSA level should fall below the detection limit. This may require 2-3 weeks. If it is still at a high level after 2-3 weeks, it must be assumed that residual tumor is present.
21 Androgen deprivation therapy may have direct effect on the PSA level that is independent of the antitumor effect. This subject must be considered always.
22 HORMONES Calcitonin Calcitonin is a hormone which decreases blood calcium concentration. Its elevated level is usually associated with medullary thyroid cancer. Calcitonin levels appear to correlate with tumor volume and metastasis. Calcitonin is also useful for monitoring treatment and detecting the recurrence of cancer.
23 However calcitonin levels l are also at a high levels in some patients with cancer of lung, breast, kidney, liver and in nonmalignant conditions such as pulmonary diseases, pancreatitis, Paget s disease, hyperparathyroidism, myeloproliferative disordes and pregnancy.
24 Human Chorionic Gonadotropin (hcg) It is a glycoprotein appears in pregnancy. Its high levels is a useful marker for tumors of placenta and some tumors of testes. hcg is also at a high level in patients with primary testes insufficiency. hcg does not cross the blood-brain brain barier. Higher levels may indicate metastase to brain.
25 ONCOFETAL ANTIGENS Most reliable markers in this group are α-fetoprotein and carcinoembryonic antigen (CEA)
26 α-fetoprotein (AFP) α-fetoprotein f is a marker for hepatocellular and germ cell carcinoma. It is also increased in pregnancy and chronic liver diseases. AFP is useful for screening (AFP levels l greater than 1000 µg/l are indicative for cancer except pregnancy), determining prognosis and monitoring therapy of liver cancers.
27 AFP is also a prognostic indicator of survival. Serum AFP levels l is less than 10 µg/l in healthy adults. Elevated AFP levels are associated with shorter survival time. AFP and hcg combined are useful in classifying and staging g germ cell tumors.one or both markers are increased in those tumors.
28 Carcinoembryonic antigen (CEA) It is a cell-surface protein and a well defined tumor marker. CEA is a marker for colorectal, gastrointestinal, lung and breast carcinoma. CEA levels are also elevated in smokers and some patients having benign conditions such as cirrhosis, rectal polyps, ulcerative colitis and benign breast disease. CEA testing should not be used for screening. Some tumors don t produce CEA. It is useful for staging and monitoring therapy.
29 CARBONHYDRATE MARKERS These markers either are antigens on the tumor cell surface or are secreted by tumor cells. They are high-molecular weight mucins or blood group antigens. Monoclonal antibodies have been developed against these antigens. Most reliable markers in this group are CA 15-3, CA 125 and CA19-9.
30 CA 15-3 CA 15-3 is a marker for breast carcinoma. Elevated CA 15-3 levels are also found in patients with pancreatic, lung, ovarian, colorectal and liver cancer and in some benign breast and liver diseases. It is not useful for diagnosis. It is g most useful for monitoring therapy.
31 CA 125 Although CA 125 is a marker for ovarian and endometrial carcinomas, it is not specific. CA 125 elevates in pancreatic, lung, breast, colorectal and gastrointestinal cancer, and in benign conditions such as cirrhosis, hepatitis, endometriosis, pericarditis and early pregnancy. It is useful in detecting residual disease in cancer patients following initial therapy.
32 A preoperative CA 125 level of less than 65 ku/l is associated with a greater 5 y survival rate than is a level greater 65 ku/l. It is also useful in differentiating benign from malignant disease in patients with ovarian masses. In the detection of recurrence use of CA In the detection of recurrence, use of CA 125 level as an indicator is about 75 % accurate.
33 CA CA is a marker for both colorectal and pancreatic carcinoma.however elevated levels were seen in patients with hepatobiliary, gastric, hepatocellular and breast cancer and in benign conditions such as pancreatitis and benign gastrointestinal diseases. CA 19-9 levels correlate with pancreatic cancer staging. It is useful in monitoring pancreatic and colorectal cancer.
34 Elevated levels el of CA can indicate recurrence before detected by radiography or clinical findings in pancreatic and colorectal cancer.
35 PROTEIN MARKERS Most reliable markers in this group are β 2 - microglobulin, ferritin, thyroglobulin and immunoglobulin. β 2 -microglobulin β 2 -microglobulin is a marker for multiple myeloma, Hodgkin lymphoma. It also increases in chronic inflammation and viral hepatitis.
36 Ferritin Ferritin is a marker for Hodgkin lymphoma, leukemia, liver, lung and breast cancer. Thyroglobulin It is a useful marker for detection of differentiated thyroid cancer.
37 Immunoglobulin: li Monoclonal l immunoglobulin has been used as marker for multiple myeloma for more than 100 years. Monoclonal paraproteins p appear as sharp bands in the globulin area of the serum protein electrophoresis. Bence-Jones protein is a free monoclonal immunoglobulin light chain in the urine and it is a reliable marker for multiple myeloma.
38 RECEPTOR MARKERS Estrogen and progesterone receptors are used in breast cancer as indicators for hormonal therapy. Patients with positive estrogen and progesterone receptors tend to respond to hormonal treatment. Those with negative receptors will be treated by other therapies.
39 Hormone receptors also serve as a prognostic factors in breast cancer. Patients with positive receptor levels tend to survive longer.
40 Cytoplasmic estrogen receptors are now routinely measured in samples of breast tissue after surgial removal of a tumor. Of patients t with breast cancer, 60 % have tumors with estrogen receptor. Approximately two thirds of patients t with estrogen receptor (+) tumors respond to the hormonal therapy. 5% of patients with estrogen receptor (-) tumors respond to the hormonal therapy.
41 Progesterone receptor testing is a useful adjunt to the estrogen receptor testing. Because progesterone receptor synthesis appears to be dependent on estrogen action. Measurement of progesterone receptors provides a confirmation that all the steps of estrogen action are intact. Indeed breast cancer patients with both progesterone and estrogen receptor (+) tumors have a higher response rate to hormonal therapy.
42 C-erbB2 (HER-2 Neu) It is receptor for epidermal growth factor (EGF) but it doesn t contain EGF binding domain. It serves as a co-receptor in EGF action In the case of increased expression of C- erbb2 leads the autoactivation and increased signal transduction
43 Increased expression of C-erbB2 was determined in some cancers. It was suggested as an important factor for carcinogenesis and metastasis
44 GENETIC CHANGES Four classes of genes are implicated in development of cancer: 1) protooncogenes which are responsible for normal cell growth and differentiation 2) tumor suppressor genes which are involved in recognition and repair of damaged DNA. 3)apoptosis-related genes are responsible for regulation of apoptosis 4)DNA repair genes Alterations on these genes may lead tumor Alterations on these genes may lead tumor development.
45 Susceptible protooncogenes: K-ras, N-ras mutations are found to be, correlated acute myeloid leukemia, neuroblastoma
46 Susceptible DNA repair genes: BRCA1 and BRCA2 are specific genes in inherited predisposition for developing breast and ovary cancer, and mutations on these genes are newly measured in some laboratories. Mismatch-repair genes are mutated in some colon cancers
47 Susceptible tumor suppressor genes: Retinoblastoma gene P53 gene P21 gene e Those genetic markers are very new and not routinely measured in laboratories.
48 Chromosomal translocation ti c-myc gene has been found to be translocated from 8.chromosom to 14. chromosom and than become activated in Burkitt s lymphoma. myc gene encodes a DNA-binding protein which stimulates cell dividing.
49 In chronic myeloid leukemia, there is a translocation between chromosomes 9 and 22.
Tumor Markers Yesterday, Today & Tomorrow Steven E. Zimmerman M.D. Vice President & Chief Medical Director Tumor Marker - Definition Substances produced by cancer cells or other cells in response to cancer
Biochemistry of Cancer and Tumor Markers The term cancer applies to a group of diseases in which cells grow abnormally and form a malignant tumor. It is a long term multistage genetic process. The first
Tumor Immunology Tumor (latin) = swelling benign tumor malignant tumor Tumor immunology : the study of the types of antigens that are expressed by tumors how the immune system recognizes and responds to
Link full download:https://getbooksolutions.com/download/test-bank-for-robbinsand-cotran-pathologic-basis-of-disease-9th-edition-by-kumar Test Bank for Robbins and Cotran Pathologic Basis of Disease 9th
PATHOPHYSIOLOGY Name Chapter 9, Part 1: Biology of Cancer and Tumor Spread I. Cancer Characteristics and Terminology Neoplasm new growth, involves the overgrowth of tissue to form a neoplastic mass (tumor).
F E A T U R E By Timothy K. Egan Before placement in a computed tomography scanner, a patient is fitted with an immobilization device. Immobilization ensures that the same area of the patient is scanned
CHAPTER 19 THE ORGANIZATION AND CONTROL OF EUKARYOTIC GENOMES Section D: The Molecular Biology of Cancer 1. Cancer results from genetic changes that affect the cell cycle 2. Oncogene proteins and faulty
Bihong Zhao, M.D, Ph.D Department of Pathology 04-28-2009 Is tumor self or non-self? How are tumor antigens generated? What are they? How does immune system respond? Introduction Tumor Antigens/Categories
American Society of Cytopathology Core Curriculum in Molecular Biology American Society of Cytopathology Core Curriculum in Molecular Biology Chapter 1 Molecular Basis of Cancer Molecular Oncology Keisha
Ovarian Cancer Causes, Risk Factors, and Prevention Risk Factors A risk factor is anything that affects your chance of getting a disease such as cancer. Learn more about the risk factors for ovarian cancer.
Tumor immunology Interaction between the immune system and tumor elimination (immune system attempts to kill cancer cells and inhibits tumor growth) balance (between elimination and growth of tumor cells)
Genetics and Cancer Ch 20 Cancer is genetic Hereditary cancers Predisposition genes Ex. some forms of colon cancer Sporadic cancers ~90% of cancers Descendants of cancerous cells all cancerous (clonal)
Evaluation of Acid and Alkaline Phosphates in Benign Prostatic Hyperplasia and Prostatic Cancer Azad Mohammed Kamal Elden Abstract Tumors of prostate are common diseases that afflict the aging male population
142 8. Cell Cycle and Cancer NOTES CELL CYCLE G 0 state o Resting cells may re-enter the cell cycle Nondividing cells (skeletal and cardiac muscle, neurons) o Have left the cell cycle and cannot undergo
MARTIN FLEISHER, PH.D., FACB MEMORIAL SLOAN-KETTERING CANCER CENTER NEW YORK, N.Y. FLEISHEM@MSKCC.ORG The Ideal Tumor Marker Quantitative level of TM reflects tumor burden with high diagnostic sensitivity
What All of Us Should Know About Cancer and Genetics Beth A. Pletcher, MD, FAAP, FACMG Associate Professor of Pediatrics UMDNJ- New Jersey Medical School Disclosures I have no relevant financial relationships
Lecture 8 Neoplasia II Dr. Nabila Hamdi MD, PhD ILOs Understand the definition of neoplasia. List the classification of neoplasia. Describe the general characters of benign tumors. Understand the nomenclature
Cover Layout 1 A Patient s Guide Understanding Tumor Markers for Breast and Colorectal Cancers Recommendations of the American Society of Clinical Oncology ... Cover Layout 2 A Patient s Guide Understanding
1 Cancer A. What is it? - A cancer is an uncontrolled, independent proliferation of robust, healthy cells. * In some the rate is fast; in others, slow; but in all cancers the cells never stop dividing.
Chapt. 18 Cancer Molecular Biology of Cancer Student Learning Outcomes: Describe cancer diseases in which cells no longer respond Describe how cancers come from genomic mutations (inherited or somatic)
Questions about cancer What is cancer? Cancer Gil McVean, Department of Statistics, Oxford What causes unregulated cell growth? What regulates cell growth? What causes DNA damage? What are the steps in
PRODUCT I N FOR MATION Fujirebio Diagnostics EIA Kit Only available outside the US Working Together for Better Diagnostics Introduction Features and Benefits of EIA kits from Fujirebio Diagnostics Simple
Tumor immunology Tried to make things a simple as they can get,,, hope that u enjoy it! ال تخافوا بس أربع صفحات وشوي Tumors can occur, they can be considered as something foreign that should be dealt with
+ Cancer Prevention & Control in Adolescent & Young Adult Survivors NCPF Workshop July 15-16, 2013 Patricia A. Ganz, MD UCLA Schools of Medicine & Public Health Jonsson Comprehensive Cancer Center + Overview
QOPI5 Chemotherapy administered to patients with metastatic solid tumor with performance status of 3, 4, or undocumented (Lower Score - Better) Percentage of adult patients with metastatic solid tumors
168 IARC MONOGRAPHS VOLUME 91 5. Summary of Data Reported and Evaluation 5.1 Exposure data The first oral hormonal contraceptives that were found to inhibit both ovulation and implantation were developed
CANCER IMMUNOPATHOLOGY Eryati Darwin Faculty of Medicine Andalas University Padang 18 Mei 2013 INTRODUCTION Tumor: cells that continue to replicate, fail to differentiate into specialized cells, and become
Clinical indications for positron emission tomography Oncology applications Brain and spinal cord Parotid Suspected tumour recurrence when anatomical imaging is difficult or equivocal and management will
Agro/Ansc/Bio/Gene/Hort 305 Fall, 2017 MEDICAL GENETICS AND CANCER Chpt 24, Genetics by Brooker (lecture outline) #17 INTRODUCTION - Our genes underlie every aspect of human health, both in function and
Diseases of the breast (2 of 2) Breast cancer Epidemiology & etiology The most common type of cancer & the 2 nd most common cause of cancer death in women 1 of 8 women in USA Affects 7% of women Peak at
Chapter 18- Oncogenes, tumor suppressors & Cancer - Previously we have talked about cancer which is an uncontrolled cell proliferation and we have discussed about the definition of benign, malignant, metastasis
The Role of Obesity and Diabetes in Cancer JOEL RUSH MS RD CSO LD CNSC FAND UT M. D. ANDERSON CANCER CENTER HOUSTON TEXAS Objectives Differentiate between modifiable cancer risk factors and non-modifiable
Chapter 3 Neoplasms Terminology Related to Neoplasms and Tumors Neoplasm New growth Tumor Swelling or neoplasm Leukemia Malignant disease of bone marrow Hematoma Bruise or contusion Classification of Neoplasms
Cancer Fundamentals Julie Randolph-Habecker, Ph.D. Director, Experimental Histopathology Shared Resource Cancer Overview Leading cause of death in US 1.2 million diagnosed each year More common after age
18 The proliferation marker thymidine kinase 1 in clinical use (Review) Ji Zhou, Ellen He and Sven Skog Sino-Swed Molecular Bio-Medicine Research Institute, Shenzhen 518057, P.R. China Received May 16,
BRCAplus genetic testing for hereditary breast cancer Developed in collaboration with Fox Chase Cancer Center and the Arcadia University Genetic Counseling Program. Causes of Hereditary Breast Cancer familial
Genetics and Cancer ERICA L SILVER, MS, LCGC GENETIC COUNSELOR Genetics 101 Transcription vs Translation 1 Carcinogenesis and Genetics Normal cell First mutation First mutation Second mutation Second mutation
Page 1 of 10 PATIENT EDUCATION Chronic Lymphocytic Leukemia (CLL) Introduction Chronic lymphocytic leukemia (CLL) is a type of cancer of the lymphocytes (a kind of white blood cell). It is also referred
The Genetics Consultation in OB-GYN : Hereditary cancers Célia DeLozier-Blanchet Division of Medical Genetics, Geneva University Hospital It is probable that all cancers are genetic! genetic vs. hereditary
Genomics and Genetic Testing Copyright 2017 Myriad Genetics, Inc., all rights reserved. www.myriad.com Why is genetic testing important to you? Impact on immediate treatment decisions Identify risks for
Testicular Cancer Scenario: A 40-year-old male presents to the surgical out-patient clinic with a 6-8 week history of a painless lump in his left scrotum. He however complains of a dull ache in the scrotum
BR-MA, GI-MA and OM-MA: Immunoassays for the Tumor Markers CA15-3, CA19-9 and CA125 Paul E. C. Sibley, Ph.D. EURO/DPC Limited BR-MA, GI-MA and OM-MA: Immunoassays for the Tumor Markers CA15-3, CA19-9 and
GIN 2010, Korea Hemashima C and Saito H National Cancer Center of Japan When deciding to make recommendations, the local situation and evidence should be considered. We compared the cancer screening guidelines
Familial and Hereditary Colon Cancer Aasma Shaukat, MD, MPH, FACG, FASGE, FACP GI Section Chief, Minneapolis VAMC Associate Professor, Division of Gastroenterology, Department of Medicine, University of
Biomarkers: An approach to targeting SMARCB1-deficient sarcomas Description The basis for dual targeting SMARCB1-deficient sarcomas with inhibitors towards PDGFRalpha and FGFR1. Key publications Wong et
Practice of Medicine-1 Ovarian Cancer Clinical Correlation Amir A. Jazaeri, M.D. Assistant Professor, Division of Gynecologic Oncology American Cancer Society Female Cancers 2000 Statistics Reprinted by
Immune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment 1 Introductions Peter Langecker, MD, PhD Executive Medical Director, Global Oncology Clinipace Worldwide Mark Shapiro Vice President
Hypercalcaemia Definition Elevated Adjusted Calcium > 2.6 mmol/l (adjusted for albumin), taken without using a cuff. Mild (usually no symptoms) 2.6 3.0 mmol/l Moderate (start to develop symptoms) 3.0 3.4
If you need more information, you can call 6722 2293 (Mon-Fri, 9am-5pm), email our Financial Protection Specialists at firstname.lastname@example.org or visit any of our OCBC branches. Q1. What is this Early Cancer
Genetics of Pancreatic Cancer October 6, 2016 If you experience technical difficulty during the presentation: Contact WebEx Technical Support directly at: US Toll Free: 1-866-229-3239 Toll Only: 1-408-435-7088
the HLA complex Hanna Mustaniemi, 28.11.2007 The Major Histocompatibility Complex Major histocompatibility complex (MHC) is a gene region found in nearly all vertebrates encodes proteins with important
www.dayspring.sg tel: +65 6339 9339 add: 290 Orchard Road #16-10 Paragon Tower Lobby 2 Singapore 238859 Your health is a gift to yourself and your family. Dayspring s offers a comprehensive range of baseline
Colorectal Cancer Screening December 5, 2017 Connecticut Cancer Partnership 14th Annual Meeting Xavier Llor, M.D., PhD. Associate Professor of Medicine Co-Director, Cancer Genetics and Prevention Program
III. Oncogenic RNA Viruses - HTLV-1 is associated with T cell Leukemia/lymphoma that is endemic in certain parts of Japan and the Caribbean - HTLV-1 has tropism for CD4+ T cell and human infection requires
Breast Cancer 100: Overview of Breast Cancer in Native Americans Native American Cancer Research A Native operated non-profit corporation 3022 South Nova Road Pine, CO 80470-7830 Phone: 303-838-9359 Fax:
The mutations that drive cancer Paul Edwards Department of Pathology and Cancer Research UK Cambridge Institute, University of Cambridge Previously on Cancer... hereditary predisposition Normal Cell Slightly
396 Cancer Inheritance STEVEN A. FRANK Asingle inherited mutant gene may be enough to cause a very high cancer risk. Single-mutation cases have provided much insight into the genetic basis of carcinogenesis,
Dominant Acting Oncogenes Eugene E. Marcantonio, M.D. Ph.D. Oncogenes are altered forms of normal cellular genes called proto-oncogenes that are involved in pathways regulating cell growth, differentiation,
University Gynecologic Oncology Associates Medical History Form Date: Name: Date of Birth: / / GYNE HISTORY Age of first period? If you no longer have periods, at what age did they stop? Are you pregnant
A tumor profile and adapted cancer surveillance in Down syndrome Daniel Satgé Pathology, University Hospital, Saint Etienne, France and ONCODEFI Project IURC Montpellier, France Michel Vekemans Labratory
Immune surveillance 5% of patients with genetic immunodeficiency develop a cancer during their lifetime (200x) Transplanted patients following an immunosuppressor therapy are 80 times more likely to develop
Sutter Health Plus Effective for Calendar Year 2015 CPTs CPT Descriptions 2015 Cost Under Deducible (Single Unit) Doctor's Office Visit for a New Patient (Also Urgent Care) 99201 Low Level Visit $99.00
Cancer in Halton Halton Region Cancer Incidence and Mortality Report 2008 2012 The Regional Municipality of Halton March 2017 Reference: Halton Region Health Department, Cancer in Halton: Halton Region
Clinical Medicine: Cancer Present State of Gene Diagnosis and Future Prospects JMAJ 45(3): 118 124, 2002 Eiichi TAHARA Chairman, Hiroshima Cancer Seminar Foundation Abstract: The entire base sequence of
Bud Mishra Room 1002, 715 Broadway, Courant Institute, NYU, New York, USA L#5:(October-18-2010) Cancer and Signals Outline 1 2 Outline 1 2 Cancer is a disease of malfunctioning cells. Cell Lineage: Adult
BSO, HRT, and ERT Jubilee Brown, MD Professor & Associate Director, Gynecologic Oncology Levine Cancer Institute at the Carolinas HealthCare System Charlotte, North Carolina No relevant financial disclosures